Table 1.
Clinical characteristics according to baseline albuminuria group
| Normo (n = 289) | Micro (n = 157) | Macro (n = 51) | |
|---|---|---|---|
| Gender (% male) | 50.5 | 65.0 | 66.7 |
| No. of AER measurementsa | 19 (8) | 21 (8) | 16 (8) |
| Duration of Follow-up (years)a | 8.5 (3.0) | 8.7 (3.1) | 6.5(2.8) |
| ACEi/ARB use (%) | 51.9 | 77.6 | 80.4 |
| Smoking (%) | 48.9 | 55.6 | 54.9 |
| Age (years)b | 66 (55, 73) | 65 (58, 71) | 64 (56, 69) |
| Diabetes duration (years)b | 9.80 (5.36, 17.26) | 11.40 (6.22, 17.29) | 13.00(8.077, 21.41) |
| SBP (mmHg)a | 139.4 (15.87) | 142.39 (15.12) | 143.58 (15.93) |
| BMI (kg/m2)a | 29.10 (26.15, 33.33) | 30.28 (27.11, 34.68) | 32.11 (28.43, 34.21) |
| HbA1c (%)a | 7.7 (1.4) | 8.0 (1.4) | 7.7 (1.8) |
| eGFR (ml/min/1.73m2)a | 74.6 (19.25) | 70.69 (19.25) | 55.01 (22.25) |
| Total cholesterol (mmol/L)a | 5.02 (0.99) | 4.95 (0.92) | 4.94 (1.13) |
| HDL-Cholesterol (mmol/L)a | 1.17 (0.96, 1.4) | 1.09 (0.88, 1.29) | 1.01 (0.88, 1.19) |
amean ± SD
bmedian (IQR)
ACEi/ARB angiotensin converting enzyme inhibitor/ angiotensin receptor blocker
SBP systolic blood pressure
HbA1c glycated haemoglobin
eGFR estimated glomerular filtration rate